No Data
US Stock MarketDetailed Quotes
LLY Eli Lilly and Co
Watchlist
584.040
-7.000-1.18% Close 12/01 16:00 ET
583.890-0.150-0.03%
Pre 08:25 ET
601.970High583.000Low3.64MVolume
591.700Open591.040Pre Close2.15BTurnover0.38%Turnover Ratio105.80P/E (TTM)554.43BMarket Cap628.80552wk High84.64P/E (Static)949.31MShares299.18252wk Low49.41P/B553.45BFloat Cap628.805Historical High4.37Dividend TTM947.62MShs Float17.323Historical Low0.75%Div YieldTTM3.21%Amplitude590.019Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Eli Lilly and Co Company
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Revenue Breakdown
Business
Currency:USD
2022/12/31
Stock NameRevenueRatio
Trulicity ®7.44B26.07%
Other6.33B22.19%
Verzenio ®2.48B8.70%
Taltz ®2.48B8.70%
Jardiance2.07B7.24%
Humalog ®2.06B7.22%
COVID-19 Antibodies2.02B7.09%
Other products1.66B5.83%
Humulin ®1.02B3.57%
Cyramza ®971.4M3.40%
View all
News
FDA Grants Second Conditional Approval For Eli Lilly's Rare Blood Cancer Drug
Friday, the FDA approved Eli Lilly and Co's (NYSE: LLY) Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) wh
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Roche Holding AG (OTC:RHHBY) has agreed to acquire a privately held obesity company Carmot Therapeutics, seeking to challenge the dominance of weight-loss drugs from Novo Nordisk A/S (NYSE:NVO) and El
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding...
Comments
Jefferies analyst claims that Roche's acquisition of Carmot's lead asset, combined with its muscle-preserving candidates, could provide a competitive edge in the market race for comorbidity-handling weight-loss drugs.
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It's Hoping to Compete With Eli Lilly, Novo Nordisk. -- Barrons.com
Pfizer Halts Development of Twice-Daily Weight Loss Pill
$Pfizer(PFE.US$
Details:
Pfizer discontinues its twice-daily experimental weight loss pill due to high rates of adverse side effects.
The pill showed significant weight loss in patients but faced low tolerance in a mid-stage clinical study.
Phase two trial data for a once-a-day version of the drug expected in the first half of 2024.
Pfizer's shares fell 4% in premarket trading after announcing the trial results.
The discontinuation ma...
Details:
Pfizer discontinues its twice-daily experimental weight loss pill due to high rates of adverse side effects.The pill showed significant weight loss in patients but faced low tolerance in a mid-stage clinical study.Phase two trial data for a once-a-day version of the drug expected in the first half of 2024.Pfizer's shares fell 4% in premarket trading after announcing the trial results.The discontinuation ma...
9
Eli Lilly's $Eli Lilly and Co(LLY.US$ Mounjaro is reportedly more effective for weight loss than Novo Nordisk's $Novo-Nordisk A/S(NVO.US$ Ozempic in overweight or obese adults, according to a large analysis of real-world data - CNBC
2
Read more
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--